Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Accounts Payables (2017 - 2025)

Organogenesis Holdings (ORGO) has 9 years of Accounts Payables data on record, last reported at $31.9 million in Q4 2025.

  • For Q4 2025, Accounts Payables rose 10.51% year-over-year to $31.9 million; the TTM value through Dec 2025 reached $31.9 million, up 10.51%, while the annual FY2025 figure was $31.9 million, 10.51% up from the prior year.
  • Accounts Payables reached $31.9 million in Q4 2025 per ORGO's latest filing, down from $40.2 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $40.2 million in Q3 2025 and bottomed at $23.2 million in Q1 2024.
  • Average Accounts Payables over 5 years is $29.5 million, with a median of $29.1 million recorded in 2021.
  • Peak YoY movement for Accounts Payables: decreased 29.43% in 2023, then skyrocketed 67.78% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $29.3 million in 2021, then grew by 10.19% to $32.3 million in 2022, then decreased by 4.97% to $30.7 million in 2023, then fell by 5.9% to $28.9 million in 2024, then grew by 10.51% to $31.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $31.9 million in Q4 2025, $40.2 million in Q3 2025, and $29.7 million in Q2 2025.